CoChat

The Use of Stem Cells as a Potential Treatment Method for Selected Neurodegenerative Diseases: Review

Open access
Cecerska-Heryć, Elżbieta, Pękała, Maja, Serwin, Natalia, Gliźniewicz, Marta, Grygorcewicz, Bartłomiej, Michalczyk, Anna, Heryć, Rafał, Budkowska, Marta, Dołęgowska, Barbara · 2023 · Cellular and Molecular Neurobiology
Cited by 59

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Abstract

Stem cells have been the subject of research for years due to their enormous therapeutic potential. Most neurological diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD) are incurable or very difficult to treat. Therefore new therapies are sought in which autologous stem cells are used. They are often the patient's only hope for recovery or slowing down the progress of the disease symptoms. The most important conclusions arise after analyzing the literature on the use of stem cells in neurodegenerative diseases. The effectiveness of MSC cell therapy has been confirmed in ALS and HD therapy. MSC cells slow down ALS progression and show early promising signs of efficacy. In HD, they reduced huntingtin (Htt) aggregation and stimulation of endogenous neurogenesis. MS therapy with hematopoietic stem cells (HSCs) inducted significant recalibration of pro-inflammatory and immunoregulatory components of the immune system. iPSC cells allow for accurate PD modeling. They are patient—specific and therefore minimize the risk of immune rejection and, in long-term observation, did not form any tumors in the brain. Extracellular vesicles derived from bone marrow mesenchymal stromal cells (BM-MSC-EVs) and Human adipose-derived stromal/stem cells (hASCs) cells are widely used to treat AD. Due to the reduction of Aβ42 deposits and increasing the survival of neurons, they improve memory and learning abilities. Despite many animal models and clinical trial studies, cell therapy still needs to be refined to increase its effectiveness in the human body. Graphical Abstract

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s10571-023-01344-6

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Research works printed but not linked: 156

  1. Ager RR et al (2015) Human neural stem cells improve cognition and promote synaptic growth in two complementary transgenic models of alzheimer’s disease and neuronal loss. Hippocampus 25(7):813–826. https://doi.org/10.1002/hipo.22405 · DOI · Paper page
  2. Al-Gharaibeh A, Culver R, Stewart AN et al (2017) Induced pluripotent stem cell-derived neural stem cell transplantations reduced behavioral deficits and ameliorated neuropathological changes in YAC128 mouse model of Huntington’s disease. Front Neurosci 10(11):628. https://doi.org/10.3389/fnins.2017.00628 · DOI
  3. Ayala-Cuellar AP, Kang J-H et al (2019) Roles of mesenchymal stem cells in tissue regeneration and immunomodulation. Biomol Ther (Seoul). 27(1):25–33 · DOI · Paper page
  4. Barczewska M, Maksymowicz S, Zdolińska-Malinowska I et al (2020) Umbilical cord mesenchymal stem cells in amyotrophic lateral sclerosis: an original study. Stem Cell Rev Rep 16(5):922–932. https://doi.org/10.1007/s12015-020-10016-7 · DOI
  5. Barker RA, Mason SL, Harrower TP et al (2013) The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington’s disease. J Neurol Neurosurg Psychiatry 84(6):657–665 · DOI
  6. Bellingacci L, Mancini A, Gaetani L, Tozzi A, Parnetti L, Di Filippo M (2021) Synaptic dysfunction in multiple sclerosis: a red thread from inflammation to network disconnection. Int J Mol Sci 22:9753 · DOI
  7. Berry JD, Cudkowicz ME, Windebank AJ, Staff NP et al (2019) NurOwn, phase 2, randomized, clinical trial in patients with ALS: Safety, clinical, and biomarker results. Neurology 93(24):e2294–e2305 · DOI · Paper page
  8. Boika A, Aleinikava N, Chyzhyk V, Zafranskaya M, Nizheharodava D, Ponomarev V (2020) Mesenchymal stem cells in Parkinson’s disease: Motor and nonmotor symptoms in the early posttransplant period. Surg Neurol Int 11(11):380. https://doi.org/10.25259/SNI_233_2020 · DOI
  9. Bond AM, Berg DA, Lee S, Garcia-Epelboim AS, Adusumilli VS, Ming GL, Song H (2020) Differential timing and coordination of neurogenesis and astrogenesis in developing mouse hippocampal subregions. Brain Sci 10:909 · DOI
  10. Brown RH, Alhalabi A (2017) Amyotrophic lateral sclerosis. N Engl J Med 377(2):162–172 · DOI · Paper page
  11. Burkhardt MF, Martinez FJ, Wright S et al (2013) A cellular model for sporadic ALS using patient-derived induced pluripotent stem cells. Mol Cell Neurosci 56:355–364 · DOI · Paper page
  12. Burt RK, Balabanov R, Burman J et al (2019) Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: a randomized clinical trial. JAMA 321(2):165–174. https://doi.org/10.1001/jama.2018.18743 · DOI · Paper page
  13. Byrne JA (2014) Developing neural stem cell-based treatments for neurodegenerative diseases. Stem Cell Res Ther 5:72 · DOI
  14. Cable J, Fuchs E, Weissman I, Jasper H, Glass D, Rando TA, Blau H, Debnath S, Oliva A, Park S, Passegué E, Kim C, Krasnow MA (2020) Adult stem cells and regenerative medicine - a symposium report. Ann N Y Acad Sci 1462(1):27–36 · DOI
  15. Camnasio S, Carri AD, Lombardo A, Grad I, Mariotti C, Castucci A et al (2012) The first reported generation of several induced pluripotent stem cell lines from homozygous and heterozygous Huntington’s disease patients demonstrates mutation relate d enhanced lysosomal activity. Neurobiol Dis 46:41–51 · DOI · Paper page
  16. Carstens M, Haq I, Martinez-Cerrato J et al (2020) Sustained clinical improvement of Parkinson’s disease in two patients with facially-transplanted adipose-derived stromal vascular fraction cells. J ClinNeurosci 81:47–51. https://doi.org/10.1016/j.jocn.2020.09.001 · DOI
  17. Casarosa S, Bozzi Y, Conti L (2014) Neural stem cells: ready for therapeutic applications? Mol Cell Ther 2:31 · DOI
  18. Chang KA, Kim HJ, Joo Y et al (2014) The therapeutic effects of human adipose-derived stem cells in alzheimer’s disease mouse models. Neurodegener Dis 13:99–102 · DOI
  19. Chen WW, Blurton-Jones M (2012) Concise review: can stem cells be used to treat or model alzheimer’s disease? Stem Cells 30(12):2612–8. https://doi.org/10.1002/stem.1240 · DOI
  20. Chen WS, Xu PZ, Gottlob K et al (2001) Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. Genes Dev 15:2203–2208 · DOI · Paper page
  21. Chiavellini P, Canatelli-Mallat M, Lehmann M et al (2022) Therapeutic potential of glial cell line-derived neurotrophic factor and cell reprogramming for hippocampal-related neurological disorders. Neural Regen Res 17(3):469–476. https://doi.org/10.4103/1673-5374.320966 · DOI
  22. Choi KA, Hong S (2017) Induced neural stem cells as a means of treatment in Huntington’s disease. Expert OpinBiol Ther 17(11):1333–1343
  23. Connor B (2018) Concise review: the use of stem cells for understanding and treating huntington’s disease. Stem Cells 36:146–160 · DOI
  24. Cook D, Genever P (2013) Regulation of mesenchymal stem cell differentiation. Adv Exp Med Biol 786:213–229 · DOI
  25. Correale J, Gaitán MI, Ysrraelit MC, Fiol MP (2017) Progressive multiple sclerosis: from pathogenic mechanisms to treatment. Brain 140(3):527–546
  26. Coyle PK (2021) What can we learn from sex differences in MS? J Pers Med 11:1006 · DOI
  27. Cudkowicz ME, Lindborg SR, Goyal NA, et al. (2022) A randomized placebo-controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis. Muscle Nerve. 65(3):291–302. doi: https://doi.org/10.1002/mus.27472. Epub 2022 Jan 5. Erratum in: Muscle Nerve. 2022 Oct;66(4):E26-E27 · DOI
  28. Danielyan L, Beer-Hammer S, Stolzing A et al (2014) Intranasal delivery of bone marrow-derived mesenchymal stem cells, macrophages, and microglia to the brain in mouse models of alzheimer’s and parkinson’s disease. Cell Transplant 23(Suppl 1):S123-139 · DOI · Paper page
  29. Dantuma E, Merchant S, Sugaya K (2010) Stem cells for the treatment of neurodegenerative diseases. Stem Cell ResTher 1:37
  30. Dey ND, Bombard MC, Roland BP, Davidson S, Lu M, Rossignol J, Sandstrom MI, Skeel RL, Lescaudron L, Dunbar GL (2010) Genetically engineered mesenchymal stem cells reduce behavioral deficits in the YAC 128 mouse model of Huntington's disease. Behav Brain Res 25;214(2):193–200 · DOI · Paper page
  31. Di Filippo M, Mancini A, Bellingacci L, Gaetani L, Mazzocchetti P, Zelante T, La Barbera L, De Luca A, Tantucci M, Tozzi A et al (2021) Interleukin-17 affects synaptic plasticity and cognition in an experimental model of multiple sclerosis. Cell Rep 37:110094 · DOI
  32. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop Dj, Horwitz E (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8(4):315–317 · DOI · Paper page
  33. Doshmanziari M, Shirian S, Kouchakian MR, Moniri SF, Jangnoo S, Mohammadi N, Zafari F (2021) Mesenchymal stem cells act as stimulators of neurogenesis and synaptic function in a rat model of alzheimer’s disease. Heliyon 7(9):e07996. https://doi.org/10.1016/j.heliyon.2021.e07996 · DOI
  34. Drews K, Jozefczuk J, Prigione A, Adjaye J (2012) Human induced pluripotent stem cells–from mechanisms to clinical applications. J Mol Med (berl) 90(7):735–745 · DOI
  35. Dulak J (2020) Komórki macierzyste: zastosowania, perspektywy, nieporozumienia. Nauka 1:99–123 · DOI
  36. Elia CA, Tamborini M, Rasile M, Desiato G, Marchetti S, Swuec P, Mazzitelli S, Clemente F, Anselmo A, Matteoli M et al (2019) Intracerebral injection of extracellular vesicles from mesenchymal stem cells exerts reduced Aβ plaque burden in early stages of a preclinical model of alzheimer’s disease. Cells 8:1059 · DOI · Paper page
  37. Eskandari N, Boroujeni ME, Abdollahifar MA, Piryaei A, Khodagholi F, Mirbehbahani SH, Siroosi S, Moghaddam MH, Aliaghaei A, Sadeghi Y (2021) Transplantation of human dental pulp stem cells compensates for striatal atrophy and modulates neuro-inflammation in 3-nitropropionic acid rat model of Huntington’s disease. Neurosci Res 170:133–144 · DOI
  38. Farinazzo A, Angiari S, Turano et al (2018) Nanovesicles from adipose-derived mesenchymal stem cells inhibit T lymphocyte trafficking and ameliorate chronic experimental autoimmune encephalomyelitis. Sci Rep 8:7473 · DOI · Paper page
  39. Fassas A, Kimiskidis VK, Sakellari I et al (2011) Long-term results of stem cell transplantation for MS: a single-center experience. Neurology 76(12):1066–1070 · DOI
  40. Feldman EL, Boulis NM, Hur J et al (2014) Intraspinal neural stem cell transplantation in amyotrophic lateral sclerosis: phase 1 trial outcomes. Ann Neurol 75(3):363–373 · DOI · Paper page
  41. Filadi R, Pizzo P (2019) Defective autophagy and Alzheimer’s disease: is calcium the key? Neural RegenRes 14:2081–2082 · DOI
  42. Filipi T, Hermanova Z, Tureckova J, Vanatko O, Anderova AM (2020) Glial cells-the strategic targets in amyotrophic lateral sclerosis treatment. J Clin Med 9:261 · DOI
  43. Fink KD, Rossignol J, Crane AT et al (2013) Transplantation of umbilical cord-derived mesenchymal stem cells into the striata of R6/2 mice: Behavioral and neuropathological analysis. Stem Cell Res Ther 4:130 · DOI
  44. Fink KD, Deng P, Torrest A, Stewart H, Pollock K, Gruenloh W et al (2015) Developing stem cell therapies for juvenile and adult –onset Huntington’s disease. Regen Med 10:623–646 · DOI · Paper page
  45. Finkel Z, Esteban F, Rodriguez B, Fu T, Ai X, Cai L (2021) Diversity of adult neural stem and progenitor cells in physiology and disease. Cells 10(8):2045 · DOI
  46. Frausin S, Viventi S, VergaFalzacappa L, Quattromani MJ, Leanza G, Tommasini A et al (2015) Wharton’s jelly derived mesenchymal stromal cells: biological properties, induction of neuronal phenotype and current applications in neurodegeneration research. Acta Histochem 117:329–338 · DOI
  47. Friedenstein AJ, Chailakhjan RK, Lalykina KS (1970) The development of fibroblast colonies in monolayer cultures of guineapig bone marrow and spleen cells. Cell Tissue Kinet 3:393–403
  48. Gbaguidi B, Guillemin F, Soudant M, Debouverie M, Mathey G, Epstein J (2022) Age-period-cohort analysis of the incidence of multiple sclerosis over twenty years in Lorraine France. Sci Rep 12:1001 · DOI
  49. Giacomelli E, Vahsen BF, Calder EL, Xu Y, Scaber J, Gray E, Dafinca R, Talbot K, Studer L (2022) Human stem cell models of neurodegeneration: From basic science of amyotrophic lateral sclerosis to clinical translation. Cell Stem Cell 29(1):11–35 · DOI
  50. Glass JD, Boulis NM, Johe K et al (2012) Lumbar intraspinal injection of neural stem cells in patients with amyotrophic lateral sclerosis: results of a phase I trial in 12 patients. Stem Cells 30(6):1144–1151 · DOI · Paper page
  51. Gójska A, Michal Nyka AW (2008) Stemcells in neurology. AktualnNeurol 8(1):39–48
  52. Guo W et al (2012) Isolation of multipotent neural stem or progenitor cells from both the dentate gyrus and subventricular zone of a single adult mouse. Nat Protoc 7(11):2005–2012. https://doi.org/10.1038/nprot.2012.123 · DOI · Paper page
  53. Guo X, Disatnik M-H, Monbureau M, Shamloo M, Mochly-Rosen D, Qi X (2013) Inhibition of mitochondrial fragmentation diminishes Huntington’s disease-associated neurodegeneration. J Clin Invest 123:5371–88 · DOI · Paper page
  54. Gurusamy N, Alsayari A, Rajasingh S, Rajasingh J (2018) Adult stem cells for regenerative therapy. Prog Mol Biol Transl Sci 160:1–22 · DOI
  55. Ha S, Ahn S, Kim S et al (2014) In vivo imaging of human adipose-derived stem cells in alzheimer’s disease animal model. J Biomed Opt 19:051206 · DOI
  56. Haji N, Mandolesi G, Gentile A, Sacchetti L, Fresegna D, Rossi S, Musella A, Sepman H, Motta C, Studer V et al (2012) TNF -α-mediated anxiety in a mouse model of multiple sclerosis. Exp Neurol 237:296–303. https://doi.org/10.1016/j.expneurol.2012.07.010 · DOI · Paper page
  57. Hallett PJ, Cooper O, Sadi D, Robertson H, Mendez I, Isacson O (2014) Long-term health of dopaminergic neuron transplants in Parkinson’s disease patients. Cell Rep 7(6):1755–61. https://doi.org/10.1016/j.celrep.2014.05.027 · DOI · Paper page
  58. Harris VK, Yan QJ, Vyshkina T, Sahabi S, Liu X, Sadiq SA (2012) Clinical and pathological effects of intrathecal injection of mesenchymal stem cell-derived neural progenitors in an experimental model of multiple sclerosis. J Neurol Sci 313:167–177 · DOI
  59. Harris VK, Stark JW, Yang S et al (2020) Mesenchymal stem cell-derived neural progenitors in progressive MS: Two-year follow-up of a phase I study. Neurol Neuroimmunol Neuroinflamm 8(1):e928. https://doi.org/10.1212/NXI.0000000000000928 · DOI
  60. Hass R, Kasper C, Böhm S, Jacobs R (2011) Different populations and sources of human mesenchymal stem cells (MSC): a comparison of adult and neonatal tissuederived MSC. Cell Commun Signal 9:12 · DOI · Paper page
  61. Hayashi Y, Lin HT, Lee CC, Tsai KJ (2020) Effects of neural stem cell transplantation in Alzheimer’s disease models. J Biomed Sci 27(1):29. https://doi.org/10.1186/s12929-020-0622-x · DOI
  62. Hedayatpour A, Ragerdi I, Pasbakhsh P, Kafami L, Atlasi N, PirhajatiMahabadi V et al (2013) Promotion of remyelination by adipose mesenchymal stem cell transplantation in a cuprizone model of multiple sclerosis. Cell J 15:142–151
  63. Hermann A, Storch A (2013) Induced neural stem cells (iNSCs) in neurodegenerative diseases. J Neural Transm (vienna) 120(Suppl 1):S19–S25. https://doi.org/10.1007/s00702-013-1042-9 · DOI
  64. Hulisz D (2018) Amyotrophic lateral sclerosis: disease state overview. Am J Manag Care 24(15 Suppl):S320–S326
  65. Islam J, So KH, Kc E, Moon HC, Kim A, Hyun SH, Kim S, Park YS (2021) Transplantation of human embryonic stem cells alleviates motor dysfunction in AAV2-Htt171-82Q transfected rat model of Huntington’s disease. Stem Cell Res Ther 12(1):585 · DOI
  66. Je G, Keyhanian K, Ghasemi M (2021) Overview of stem cells therapy in amyotrophic lateral sclerosis. Neurol Res 43(8):616–632 · DOI
  67. Jiang Q, Huang K, Lu F et al (2022) Modifying strategies for SDF-1/CXCR4 interaction during mesenchymal stem cell transplantation. Gen Thorac Cardiovasc Surg 70(1):1–10. https://doi.org/10.1007/s11748-021-01696-0 · DOI · Paper page
  68. Justyna Kacperska M, Dominika Książek-Winiarek, Karol Jastrzębski, et al. (2013) The attempts to use stem cells in the therapy of selected disorders of the nervous system”, Aktualn Neurol. 13(2): 145–156
  69. Karussis D, Karageorgiou C, Vaknin-Dembinsky A (2010) Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol 67(10):1187–119 · DOI · Paper page
  70. Kassis I, Grigoriadis N, Gowda-Kurkalli B, Mizrachi-Kol R, Ben-Hur T, Slavin S et al (2008) Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis. Arch Neurol 65:753–761 · DOI · Paper page
  71. Kaufmann M, Evans H, Schaupp AL, Engler JB, Kaur G, Willing A, Kursawe N, Schubert C, Attfield KE, Fugger L et al (2021) Identifying CNS-colonizing T cells as potential therapeutic targets to prevent progression of multiple sclerosis. Med 2:296-312.e8 · DOI · Paper page
  72. Kawaguchi A (2020) Neuronal delamination and outer radial glia generation in neocortical development. Front Cell Dev Biol 8:623573. https://doi.org/10.3389/fcell.2020.623573 · DOI
  73. Killoran A, Biglan KM, Jankovic J, Eberly S, Kayson E, Oakes D et al (2009) Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS. Neurology 87(1):26–33. https://doi.org/10.1002/jnr.21817 · DOI
  74. Killoran A, Biglan KM, Jankovic J, Eberly S, Kayson E, Oakes D et al (2013) Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS. Neurology 80:2022 · DOI
  75. Kim HJ, Cho KR, Jang H, Lee NK, Jung YH, Kim JP, Lee JI, Chang JW, Park S, Kim ST, Moon SW, Seo SW, Choi SJ, Na DL (2021a) Intracerebroventricular injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer’s disease dementia: a phase I clinical trial. Alzheimers Res Ther 13(1):154. https://doi.org/10.1186/s13195-021-00897-2 · DOI · Paper page
  76. Kim A, Lalonde K, Truesdell A, Gomes Welter P, Brocardo PS, Rosenstock TR, Gil-Mohapel J (2021b) New Avenues for the treatment of Huntington’s disease. Int J Mol Sci 22(16):8363 · DOI · Paper page
  77. Kim A, Lalonde K, Truesdell A et al (2021c) New avenues for the treatment of Huntington’s disease. Int J Mol Sci 22(16):8363. https://doi.org/10.3390/ijms22168363 · DOI · Paper page
  78. Knippenberg S, Rath KJ, Boselt S et al (2017) Intraspinal administration of human spinal cord-derived neural progenitor cells in the G93A-SOD1 mouse model of ALS delays symptom progression, prolongs survival and increases expression of endogenous neurotrophic factors. J Tissue Eng Regen Med 11(3):751–764 · DOI
  79. Kolagar TA, Farzaneh M, Nikkar N, Khoshnam SE (2020) Human pluripotent stem cells in neurodegenerative diseases: potentials, advances and limitations. Curr Stem Cell Res Ther 15(2):102–110 · DOI
  80. Kondo T, Funayama M, Tsukita K et al (2014) Focal transplantation of human iPSC-derived glial-rich neural progenitors improves lifespan of ALS mice. Stem Cell Rep 3(2):242–249 · DOI · Paper page
  81. Kopen GC, Prockop DJ, Phinney DG (1999) Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains. Proc Natl Acad Sci USA 96:10711–10716 · DOI · Paper page
  82. Lee JP et al (2008) Neural stem cell transplantation in mouse brain. Curr Protoc Neurosci. https://doi.org/10.1002/0471142301.ns0310s42 · DOI
  83. Lee JH, Liu JW, Lin SZ et al (2018) Advances in patient-specific induced pluripotent stem cells shed light on drug discovery for amyotrophic lateral sclerosis. Cell Transplant 27(9):1301–1312 · DOI
  84. Lulu S, Graves J, Waubant E (2016) Menarche increases relapse risk in pediatric multiple sclerosis. Mult Scler J 22:193–200 · DOI
  85. Ma DK, Bonaguidi MA, Ming GL, Song H (2009) Adult neural stem cells in the mammalian central nervous system. Cell Res 19:672–82 · DOI · Paper page
  86. Machaliński B (2008) Non-embryonic stem cells and regeneration of the nervous system. Pol Przegl Neurol 4(1):15–19
  87. Madrazo I, Kopyov O, Ávila-Rodríguez MA et al (2019) Transplantation of human neural progenitor cells (NPC) into putamina of parkinsonian patients: a case series study, safety and efficacy four years after surgery. Cell Transplant 28(3):269–285. https://doi.org/10.1177/0963689718820271 · DOI
  88. Martinez-Morales PL et al (2013) Progress in stem cell therapy for major human neurological disorders. Stem Cell Rev 9(5):685–699. https://doi.org/10.1007/s12015-013-9443-6 · DOI
  89. Mass RF, Vigne S, Pot C (2019) Resolution of inflammation during multiple sclerosis. Semin Immunopathol 41:711–726. https://doi.org/10.1007/s00281-019-00765-0 · DOI · Paper page
  90. Massirer KB et al (2011) Maintenance and differentiation of neural stem cells. Wiley Interdiscip Rev Syst Biol Med 3(1):107–114. https://doi.org/10.1002/wsbm.100 · DOI
  91. Mattis VB, Tom C, Akimov S, Saeedian J, Østergaard ME, Southwell AL et al (2015) HD iPSC-derived neural progenitors accumulate in culture and are susceptible to BDNF withdrawal due to glutamate toxicity. Hum Mol Genet 24:3257–71 · DOI · Paper page
  92. Mazini L, Rochette L, Amine M, Malka G (2019) Regenerative capacity of adipose derived stem cells (ADSCs), comparison with mesenchymal stem cells (MSCs). Int J Mol Sci 20(10):2523. https://doi.org/10.3390/ijms20102523.PMID:31121953;PMCID:PMC6566837 · DOI · Paper page
  93. Mazzini L, Gelati M, Profico DC et al (2015) Human neural stem cell transplantation in ALS: initial results from a phase I trial. J Transl Med 27(13):17 · DOI · Paper page
  94. McColgan P, Tabrizi SJ (2018) Huntington’s disease: a clinical review. Eur J Neurol 25(1):24–34. https://doi.org/10.1111/ene.13413 · DOI · Paper page
  95. McCoy MK, Martinez TN, Ruhn KA et al (2008) Autologous transplants of adipose-derived adult stromal (ADAS) cells afford dopaminergic neuroprotection in a model of parkinson’s disease. Exp Neurol 210:14–29 · DOI
  96. Mehta P, Kaye W, Raymond J et al (2018) Prevalence of amyotrophic lateral sclerosis —United States, 2014. MMWR Morb Mortal Wkly Rep 67(7):216–218 · DOI · Paper page
  97. Miura K, Okada Y, Aoi T et al (2009) Variation in the safety of induced pluripotent stem cell lines. Nat Biotechnol 27(8):743–745 · DOI · Paper page
  98. Morizane A, Kikuchi T, Hayashi T et al (2017) MHC matching improves engraftment of iPSC-derived neurons in non-human primates. Nat Commun 8:385. https://doi.org/10.1038/s41467-017-00926-5 · DOI · Paper page
  99. Mross K, Jankowska M, Meller A, Machowska-Sempruch K, Nowacki P, Masztalewicz M, Pawlukowska W (2022) Sensory integration disorders in patients with multiple sclerosis. J Clin Med 11:5183. https://doi.org/10.3390/jcm11175183 · DOI
  100. Mu S, Wang J, Zhou G, Peng W, He Z, Zhao Z, Mo CP, Qu J, Zhang J (2014) Transplantation of induced pluripotent stem cells improves functional recovery in Huntington’s disease rat model. PLoS ONE 9:101185 · DOI
  101. Munter J, Shafarevich I, Liundup A et al (2020) Neuro-Cells therapy improves motor outcomes and suppresses inflammation during experimental syndrome of amyotrophic lateral sclerosis in mice. CNS Neurosci Ther 26(5):504–517 · DOI
  102. Muraro PA, Pasquini M, Atkins HL et al (2017a) Long-term outcomes after autologous hematopoietic stem cell transplantation for multiple sclerosis. JAMA Neurol 74:459–469 · DOI · Paper page
  103. Muraro PA, Martin R, Mancardi GL et al (2017b) Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis. Nat Rev Neurol 13:391–405 · DOI · Paper page
  104. Myhr KM, Torkildsen O, Lossius A, Bo L, Holmoy T (2019) B cell depletion in the treatment of multiple sclerosis. Expert Opin Biol Ther 19:261–271 · DOI
  105. Namzaric (2016) (memantine and donepezil hydrochlorides). Full Prescribing Information. Allergan USA Inc, Irvine
  106. Nizzardo M, Simone C, Rizzo F et al (2014) Minimally invasive transplantation of iPSC-derived ALDHhiSSCloVLA4+ neural stem cells effectively improves the phenotype of an amyotrophic lateral sclerosis model. Hum Mol Genet 23(2):342–354 · DOI
  107. Papoutsi M, Labuschagne I, Tabrizi SJ, Stout JC (2014) The cognitive burden in Huntington’s disease: pathology, phenotype, and mechanisms of compensation. MovDisord 29:673–683
  108. Park HJ, Lee PH, Bang OY et al (2008) Mesenchymal stem cells therapy exerts neuroprotection in a progressive animal model of Parkinson’s disease. J Neurochem 107:141–151 · DOI · Paper page
  109. Peng J, Zeng X (2011) The role of induced pluripotent stem cells in regenerative medicine: neurodegenerative diseases. Stem Cell ResTher 2:32
  110. Petrou P, Kassis I, Levin N, Paul F, Backner Y, Benoliel T, Oertel FC, Scheel M, Hallimi M, Yaghmour N, Hur TB, Ginzberg A, Levy Y, Abramsky O, Karussis D (2020) Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis. Brain 143(12):3574–3588 · DOI · Paper page
  111. Petrou P, Kassis I, Yaghmour NE, Ginzberg A, Karussis D (2021) A phase II clinical trial with repeated intrathecal injections of autologous mesenchymal stem cells in patients with amyotrophic lateral sclerosis. Front Biosci (landmark Ed) 26(10):693–706 · DOI
  112. Petrou P, Kassis I, Ginzberg A et al (2022) Effects of mesenchymal stem cell transplantation on cerebrospinal fluid biomarkers in progressive multiple sclerosis. Stem Cells Transl Med 11(1):55–58. https://doi.org/10.1093/stcltm/szab017.PMID:35641166;PMCID:PMC8895488 · DOI
  113. Phinney DG, Prockop DJ (2007) Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair--current views. Stem Cells 25(11):2896-902. · DOI · Paper page
  114. Popescu IR, Nicaise C, Liu S et al (2013) Neural progenitors derived from human induced pluripotent stem cells survive and differentiate upon transplantation into a rat model of amyotrophic lateral sclerosis. Stem Cells Transl Med 2(3):167–174 · DOI
  115. Quarrell O, O’Donovan KL, Bandmann O, Strong M (2012) The prevalence of juvenile Huntington’s disease: A review of the literature and meta-analysis. PLoSCurr. https://doi.org/10.1371/4f8606b742ef3 · DOI
  116. Raymond J et al (2018) Prevalence of amyotrophic lateral sclerosis—United States, 2014. MMWR Morb Mortal Wkly Rep 67(7):216–218 · DOI · Paper page
  117. Reidling JC, Relaño-Ginés A, Holley SM et al (2018) Human neural stem cell transplantation rescues functional deficits in R6/2 and Q140 Huntington’s disease mice. Stem Cell Rep 10:58–72 · DOI
  118. Rice CM, Halfpenny CA, Scolding NJ (2003) Stem cells for the treatment of neurological disease. Transfus Med 13:351–361 · DOI
  119. Ring KL, An MC, Zhang N, O’Brien RN, Ramos EM, Gao F et al (2015) Genomic analysis reveals disruption of striatal neuronal development and therapeutic targets in human Huntington’s disease neural ste m cells. Stem Cell Rep 5:1023–1038 · DOI
  120. Riordan NH, Morales I, Fernández G, Allen N, Fearnot NE, Leckrone ME, Markovich DJ, Mansfield D, Avila D, Patel AN, Kesari S, Paz RJ (2018) Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis. J Transl Med 16(1):57 · DOI · Paper page
  121. Schwarz K, Schmitz F (2023) Synapse dysfunctions in multiple sclerosis. Int J Mol Sci 24(2):1639. https://doi.org/10.3390/ijms24021639 · DOI
  122. Shahbazi E et al (2018) Reprogramming of somatic cells to induced neural stem cells. Methods 133:21–28. https://doi.org/10.1016/j.ymeth.2017.09.007 · DOI
  123. Shevchenko JL, Kuznetsov AN, Ionova TI et al (2012) Autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis. Exp Hematol 40(11):892–898 · DOI
  124. Sinenko SA, Ponomartsev SV, Tomilin AN (2020) Human artificial chromosomes for pluripotent stem cell - based tissue replacement therapy. Exp Cell Res. 389(1):111882 · DOI
  125. Siwek T, Jezierska-Woźniak K, Maksymowicz S et al (2020) Repeat administration of bone marrow-derived mesenchymal stem cells for treatment of amyotrophic lateral sclerosis. Med Sci Monit 26:e927484. https://doi.org/10.12659/MSM.927484 · doi:10.12659/msm.927484
  126. Soler R, Fullhase C et al (2012) Stem cell therapy ameliorates bladder dysfunction in an animal model of Parkinson disease. J Urol 187:1491–1497 · DOI · Paper page
  127. Stoddard-Bennett T, Reijo Pera R (2019) Treatment of parkinson’s disease through, personalized medicine and induced pluripotent stem cells. Cells 8(1):26 · DOI · Paper page
  128. Teng YD, Benn SC, Kalkanis SN et al (2012) Multimodal actions of neural stem cells in a mouse model of ALS: a meta -analysis. Sci Transl Med 4(165):161ral164 · DOI
  129. Terashima T, Kojima H, Urabe H et al (2014) Stem cell factor-activated bone marrow ameliorates amyotrophic lateral sclerosis by promoting protective microglial migration. J Neurosci Res. 92(7):856–869 · DOI
  130. Terashima T, Kobashi S, Watanabe Y et al (2020) Enhancing the therapeutic efficacy of bone marrow-derived mononuclear cells with growth factor-expressing mesenchymal stem cells for ALS in mice. iScience 23(11):101764 · DOI
  131. Tousley A, Kegel-Gleason KB (2016) Induced pluripotent stem cells in huntington’s disease research: progress and opportunity. J Huntingtons Dis 5(2):99–131 · DOI
  132. Tsiftsoglou AS (2021) Erythropoietin (EPO) as a key regulator of erythropoiesis, bone remodeling and endothelial transdifferentiation of multipotent mesenchymal stem cells (MSCs): implications in regenerative medicine. Cells 10(8):2140. https://doi.org/10.3390/cells10082140 · DOI
  133. Tuazon JP, Castelli V, Lee JY, Desideri GB, Stuppia L, Cimini AM, Borlongan CV (2019) Neural stem cells. AdvExp. Med Biol 1201:79–91
  134. Tyzack G, Lakatos A, Patani R (2016) Human stem cell-derived astrocytes: specification and relevance for neurological disorders. Curr Stem Cell Rep 2:236–247 · DOI · Paper page
  135. Uccelli A, Laroni A, Ali R, Battaglia MA, Blinkenberg M, Brundin L, Clanet M, Fernandez O, Marriot J, Muraro P, Nabavi SM, Oliveri RS, Radue E, RamoTello C, Schiavetti I, Sellner J, Sorensen PS, Sormani MP, Wuerfel JT, Freedman MS, MESEMS investigators (2021) Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial. Lancet Neurol 20(11):917–929 · DOI · Paper page
  136. Van der Meer LB, van Duijn E, Wolterbeek R, Tibben A (2012) Adverse childhood experiences of persons at risk for Huntington’s disease or BRCA1/2 hereditary breast/ovarian cancer. Clin Genet 81:18–23 · DOI
  137. Venkatesan A, Johnson RT (2014) Infections and multiple sclerosis. Handb Clin Neurol 122:151–171. https://doi.org/10.1016/B978-0-444-52001-2.00007-8 · DOI
  138. Visweswaran M, Hendrawan K, Massey JC et al (2022) (2022) Sustained immunotolerance in multiple sclerosis after stem cell transplant. Ann ClinTransl Neurol 9(2):206–220. https://doi.org/10.1002/acn3.51510 · DOI
  139. Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, Robertson N, La Rocca N, Uitdehaag B, van der Mei I et al (2020) Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS. Mult Scler J 26:1816–1821 · DOI · Paper page
  140. Watanabe Y, Kazuki Y, Kazuki K et al (2015) Use of a human artificial chromosome for delivering trophic factors in a rodent model of amyotrophic lateral sclerosis. Mol Ther Nucleic Acids 4(10):e253 · DOI
  141. Wen Y, Jin S (2014) Production of neural stem cells from human pluripotent stem cells. J Biotechnol 188:122–129. https://doi.org/10.1016/j.jbiotec.2014.07.453 · DOI
  142. Wenceslau CV, de Souza DM, Mambelli-Lisboa NC, Ynoue LH, Araldi RP, da Silva JM, Pagani E, Haddad MS, Kerkis I (2022) Restoration of BDNF, DARPP32, and D2R expression following intravenous infusion of human immature dental pulp stem cells in Huntington’s disease 3-NP rat model. Cells 11(10):1664 · DOI
  143. Wenceslau CV, Kerkis I, Pompeia C, Haddad MS (2017) Pluripotent stem cells to model and treat huntington’s disease. In: Nagehan Ersoy Tunali (Eds) Huntington’s disease—molecular pathogenesis and current models. InTech, Palm Beach · DOI
  144. Wilkins A (2017) Cerebellar dysfunction in multiple sclerosis. Front Neurol 8:312. https://doi.org/10.3389/fneur.2017.00312 · DOI
  145. Wu Y-Y, Chiu F-L, Yeh C-S et al (2019) Opportunities and challenges for the use of induced pluripotent stem cells in modeling neurodegenerative disease. OpenBiol 9:180177
  146. Xia M, Zhao T, Wang X et al (2021) Brain-derived neurotrophic factor and its applications through nanosystem delivery. Iran J Pharm Res 20(4):137–151. https://doi.org/10.22037/ijpr.2021.115705.15484 · DOI
  147. Xie C, Liu YQ, Guan YT, Zhang GX (2016) Induced stem cells as a novel multiple sclerosis therapy. Curr Stem Cell Res Ther 11(4):313–320 · DOI
  148. Xin H, Katakowski M, Wang M et al (2017) MicroRNA-17-92 cluster in exosomes enhance neuroplasticity and functional recovery after stroke in rats. Stroke 48:747–753 · DOI · Paper page
  149. Yamanaka S (2020) Pluripotent stem cell-based cell therapypromise and challenges. Cell Stem Cell 27(4):523–531. https://doi.org/10.1016/j.stem.2020.09.014 · DOI · Paper page
  150. Yan M, Sun M, Zhou Y et al (2013) Conversion of human umbilical cord mesenchymal stem cells in Wharton’s jelly to dopamine neurons mediated by the Lmx1a and neurturin in vitro: potential therapeutic application for Parkinson’s disease in a rhesus monkey model. PLoS ONE 8:e64000 · DOI
  151. Zakrzewski W, Dobrzyński M, Szymonowicz M et al (2019) Stem cells: past, present, and future. Stem Cell Res Ther 10:68 · DOI · Paper page
  152. Zhan Y, Zheng H et al (2017) A novel presenilin 1 mutation (F388L) identified in a Chinese family with early-onset Alzheimer’s disease. Neurobiol Aging 50:168e1-168e4 · DOI
  153. Zhang X, Du F, Yang D, Yu C, Huang X, Liu W et al (2010) Transplanted bone marrow stem cells relocate to infarct penumbra and co-express endogenous proliferative and immature neuronal markers in a mouse model of ischemic cerebral stroke. BMC Neurosci 11:138 · DOI
  154. Zhang K, Liu GH, Yi F et al (2014) Direct conversion of human fibroblasts into retinal pigment epithelium-like cells by defined factors. Protein Cell 5(1):48–58 · DOI
  155. Zhang W, Gu GJ, Zhang Q, Liu JH, Zhang B, Guo Y, Wang MY, Gong QY, Xu JR (2017) NSCs promote hippocampal neurogenesis, metabolic changes and synaptogenesis in APP/PS1 transgenic mice. Hippocampus 27(12):1250–1263. https://doi.org/10.1002/hipo.22794 · DOI
  156. Zhang F-Q, Jiang J-L, Zhang J-T et al (2020) Current status and future prospects of stem cell therapy in alzheimer’s disease’. Neural Regen Res 15(2):242–250 · DOI

Cited by

See all 59

Metadata

Authors
Cecerska-Heryć, E., Pękała, M., Serwin, N., Gliźniewicz, M., Grygorcewicz, B., Michalczyk, A., Heryć, R., Budkowska, M., & Dołęgowska, B.
Venue
Cellular and Molecular Neurobiology
Published
2023-04-07
Volume
43
Issue
6
Pages
2643-2673
ISSN
  • 0272-4340 (ISSN-L)
  • 1573-6830
OpenAlex
W4362693053
Cited by
59
References
28
FWCI
8.97
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Use of Stem Cells as a Potential Treatment Method for Selected Neurodegenerative Diseases: Review. https://app.cochat.ai/papers/10.1007/s10571-023-01344-6
The paper
Cecerska-Heryć, E., Pękała, M., Serwin, N., Gliźniewicz, M., Grygorcewicz, B., Michalczyk, A., Heryć, R., Budkowska, M., & Dołęgowska, B. (2023). The Use of Stem Cells as a Potential Treatment Method for Selected Neurodegenerative Diseases: Review. Cellular and Molecular Neurobiology. https://doi.org/10.1007/s10571-023-01344-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.